Cronos (CRON) Total Non-Current Liabilities (2016 - 2026)
Cronos' (CRON) quarterly Total Non-Current Liabilities came in at $47.5 million in Q1 2026, up 23.65% year-on-year from $38.5 million in Q1 2025, and down 11.04% quarter-over-quarter from $53.4 million in Q4 2025.
Cronos (CRON) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Cronos' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $47.5 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 23.65% year-over-year to $47.5 million in Q1 2026; TTM through Mar 2026 was $47.5 million, a 23.65% increase from a year earlier, with the FY2025 full-year figure at $53.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to $47.5 million in Q1 2026 per CRON's latest filing, from $53.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $73.8 million in Q4 2022 and bottomed at $30.7 million in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $45.6 million (2022), against an average of $45.2 million.
- Across the five-year window, Total Non-Current Liabilities slumped 85.45% in 2022 and soared 59.5% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $73.8 million in 2022, then declined by 12.15% to $64.8 million in 2023, then retreated by 20.42% to $51.6 million in 2024, then gained by 3.62% to $53.4 million in 2025, then declined by 11.04% to $47.5 million in 2026.
- Per Business Quant, the three latest CRON Total Non-Current Liabilities figures stand at $47.5 million (Q1 2026), $53.4 million (Q4 2025), and $45.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Cronos | 1.04 Bn | 267.78 Mn | 19.15 Mn | 47.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.55 Mn |
| Dec 31, 2025 | 53.45 Mn |
| Sep 30, 2025 | 45.66 Mn |
| Jun 30, 2025 | 44.34 Mn |
| Mar 31, 2025 | 38.45 Mn |
| Sep 30, 2024 | 51.58 Mn |
| Jun 30, 2024 | 34.12 Mn |
| Mar 31, 2024 | 34.72 Mn |
| Dec 31, 2023 | 64.81 Mn |
| Sep 30, 2023 | 32.34 Mn |
| Jun 30, 2023 | 30.65 Mn |
| Mar 31, 2023 | 33.18 Mn |
| Dec 31, 2022 | 73.78 Mn |
| Sep 30, 2022 | 46.23 Mn |
| Jun 30, 2022 | 46.68 Mn |
| Mar 31, 2022 | 45.53 Mn |
| Dec 31, 2021 | 81.59 Mn |
| Sep 30, 2021 | 44.25 Mn |
| Jun 30, 2021 | 208.70 Mn |
| Mar 31, 2021 | 313.00 Mn |